|
業務類別
|
Biotechnology |
|
業務概覽
|
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development. |
| 公司地址
| 250 West 34th Street, New York, NY, USA, 10119 |
| 電話號碼
| +1 332 282-0507 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ataibeckley.com |
| 員工數量
| 117 |
| Mr. Srinivas G. Rao, M.D.,PhD |
Chief Executive Officer and Director |
美元 629.20K |
22/04/2026 |
| Dr. Gerd Kochendoerfer, PhD |
Chief Operating Officer |
美元 440.00K |
22/04/2026 |
| Mr. Michael E. Faerm |
Chief Financial Officer |
-- |
22/04/2026 |
| Ms. Anne Nagengast Johnson |
Chief Accounting Officer |
-- |
22/04/2026 |
| Mr. Ryan Barrett |
Chief Legal Officer and Chief Business Officer |
美元 460.00K |
22/04/2026 |
| Dr. Glenn Frank Short, PhD |
Chief Scientific Officer |
-- |
22/04/2026 |
| Mr. Kevin James Craig, M.D. |
Chief Medical Officer |
-- |
22/04/2026 |
|
|
| Ms. Sabrina Martucci Johnson |
Independent Director |
22/04/2026 |
| Dr. Robert M. Hershberg, M.D.,PhD |
Independent Director |
22/04/2026 |
| Dr. Amir Kalali,M.D. |
Independent Director |
22/04/2026 |
| Mr. Srinivas G. Rao, M.D.,PhD |
Chief Executive Officer and Director |
22/04/2026 |
| Dr. Laurent Fischer, M.D. |
Independent Director |
22/04/2026 |
| Dr. Scott Braunstein, M.D. |
Vice Chairman of the Board |
22/04/2026 |
| Ms. Andrea Heslin Smiley |
Independent Director |
22/04/2026 |
| Mr. Christian Angermayer |
Chairman of the Board |
22/04/2026 |
| Mr. John Hoffman |
Independent Director |
22/04/2026 |
|
|
|
|
